@radoncdocgee.bsky.social

RadOnc PhysicianScientist, Clin A/Prof Sydney University. Adjunct Research Scientist @CMRI. Usual disclaimers.

5/ Hypothesis - all work in vitro so far so lots of provisos - would be that tumours with HR defects would respond better to the combination of SBRT/SABR and immunotherapy.

3/ This opens up new therapeutic opportunities to personalise the combination of SABR/SBRT and immunotherapy and run biomarker driven trials

2/ @thecesarelab.bsky.social has a wonderful run through of the science. Key take away for the rad onc community: timing and mode of cell death after ablative radiotherapy is dependent DNA repair pathway, with homologous recombination leading to mitotic 'non-immunogenic' cell death